Bronchopulmonary Dysplasia: 50 Years after the Original Description

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bronchopulmonary dysplasia (BPD) is one of the few diseases in neonatal medicine that has continued to evolve since its first description about 50 years ago. Over these years, advancements in neonatal medicine such as antenatal steroids and exogenous surfactant therapy have significantly reduced neonatal mortality and lowered the limits of viability for preterm infants. Although the incidence of BPD continues to be high, especially in extremely low birth weight infants, the clinical picture has evolved into a milder disease with low mortality or significant morbidities. This new BPD is the result of complex interactions between altered alveolar and vascular development, injury by ante- and postnatal pathogenic factors, and reparative processes in the lung. There has been significant progress in our understanding of risk factors for BPD, but challenges persist in its definition, and in finding effective preventive strategies. There are promising developments with newer preventive interventions such as mesenchymal stem cells, exosomes, immunomodulators, and growth factors, but they are still in preclinical stage. The future challenges include finding ways to define BPD based on the severity of lung pathology, which can better predict long-term outcomes, development of early predictors of lung disease, and finding innovative and evidence-based preventive and management strategies.

Original languageEnglish (US)
Pages (from-to)384-391
Number of pages8
JournalNeonatology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Bronchopulmonary Dysplasia
Infant, Newborn, Diseases
Medicine
Extremely Low Birth Weight Infant
Exosomes
Lung
Vascular System Injuries
Immunologic Factors
Infant Mortality
Mesenchymal Stromal Cells
Premature Infants
Surface-Active Agents
Lung Diseases
Intercellular Signaling Peptides and Proteins
Steroids
Pathology
Morbidity
Mortality
Incidence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental Biology

Cite this

Bronchopulmonary Dysplasia : 50 Years after the Original Description. / Bancalari, Eduardo; Jain, Deepak.

In: Neonatology, 01.01.2019, p. 384-391.

Research output: Contribution to journalArticle

@article{af391d4eab26473aa45857cdc4b969ad,
title = "Bronchopulmonary Dysplasia: 50 Years after the Original Description",
abstract = "Bronchopulmonary dysplasia (BPD) is one of the few diseases in neonatal medicine that has continued to evolve since its first description about 50 years ago. Over these years, advancements in neonatal medicine such as antenatal steroids and exogenous surfactant therapy have significantly reduced neonatal mortality and lowered the limits of viability for preterm infants. Although the incidence of BPD continues to be high, especially in extremely low birth weight infants, the clinical picture has evolved into a milder disease with low mortality or significant morbidities. This new BPD is the result of complex interactions between altered alveolar and vascular development, injury by ante- and postnatal pathogenic factors, and reparative processes in the lung. There has been significant progress in our understanding of risk factors for BPD, but challenges persist in its definition, and in finding effective preventive strategies. There are promising developments with newer preventive interventions such as mesenchymal stem cells, exosomes, immunomodulators, and growth factors, but they are still in preclinical stage. The future challenges include finding ways to define BPD based on the severity of lung pathology, which can better predict long-term outcomes, development of early predictors of lung disease, and finding innovative and evidence-based preventive and management strategies.",
author = "Eduardo Bancalari and Deepak Jain",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000497422",
language = "English (US)",
pages = "384--391",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Bronchopulmonary Dysplasia

T2 - 50 Years after the Original Description

AU - Bancalari, Eduardo

AU - Jain, Deepak

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bronchopulmonary dysplasia (BPD) is one of the few diseases in neonatal medicine that has continued to evolve since its first description about 50 years ago. Over these years, advancements in neonatal medicine such as antenatal steroids and exogenous surfactant therapy have significantly reduced neonatal mortality and lowered the limits of viability for preterm infants. Although the incidence of BPD continues to be high, especially in extremely low birth weight infants, the clinical picture has evolved into a milder disease with low mortality or significant morbidities. This new BPD is the result of complex interactions between altered alveolar and vascular development, injury by ante- and postnatal pathogenic factors, and reparative processes in the lung. There has been significant progress in our understanding of risk factors for BPD, but challenges persist in its definition, and in finding effective preventive strategies. There are promising developments with newer preventive interventions such as mesenchymal stem cells, exosomes, immunomodulators, and growth factors, but they are still in preclinical stage. The future challenges include finding ways to define BPD based on the severity of lung pathology, which can better predict long-term outcomes, development of early predictors of lung disease, and finding innovative and evidence-based preventive and management strategies.

AB - Bronchopulmonary dysplasia (BPD) is one of the few diseases in neonatal medicine that has continued to evolve since its first description about 50 years ago. Over these years, advancements in neonatal medicine such as antenatal steroids and exogenous surfactant therapy have significantly reduced neonatal mortality and lowered the limits of viability for preterm infants. Although the incidence of BPD continues to be high, especially in extremely low birth weight infants, the clinical picture has evolved into a milder disease with low mortality or significant morbidities. This new BPD is the result of complex interactions between altered alveolar and vascular development, injury by ante- and postnatal pathogenic factors, and reparative processes in the lung. There has been significant progress in our understanding of risk factors for BPD, but challenges persist in its definition, and in finding effective preventive strategies. There are promising developments with newer preventive interventions such as mesenchymal stem cells, exosomes, immunomodulators, and growth factors, but they are still in preclinical stage. The future challenges include finding ways to define BPD based on the severity of lung pathology, which can better predict long-term outcomes, development of early predictors of lung disease, and finding innovative and evidence-based preventive and management strategies.

UR - http://www.scopus.com/inward/record.url?scp=85064335035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064335035&partnerID=8YFLogxK

U2 - 10.1159/000497422

DO - 10.1159/000497422

M3 - Article

C2 - 30974430

AN - SCOPUS:85064335035

SP - 384

EP - 391

JO - Neonatology

JF - Neonatology

SN - 1661-7800

ER -